enteric-coated naproxen
Phase 3
enteric-coated naproxen is one of 11 therapeutic programs targeting Cellulitis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
10 competitors in Cellulitis
#DrugCompanyPhaseTrials
1Keflex
Eli LillyApproved
Acanya
PfizerApproved
Avelox
BayerApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Cubicin
BBaxter Healthcare Corporation
Approved
Levaquin
WWim Janssens
Approved
Ancef
BBaxter Healthcare Corporation
Approved
enteric-coated naproxen
OOttawa Hospital Research Institute
Phase 3
Decadron
AAspen Global Incorporated
Preclinical
Trimethoprim-Sulfamethoxazole
AstellasPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for enteric-coated naproxen. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]